Mar 23, 2014 at 15:39 | Source: PTI
"If they (the US) want a discussion in WTO (World Trade Organization), we are more than ready because we are not in any breach. We are very clear," Commerce and Industry Minister Anand Sharma told PTI.
Sep 22, 2013 at 11:58 | Source: PTI
Ranbaxy Laboratories, which was acquired by Japanese drug maker Daiichi Sankyo in 2008, commissioned the Mohali plant in 2011 and started exports from there in 2012. It is the third Ranbaxy facility in India to face FDA action, after the Dewas and Paonta Sahib plants.
Sep 17, 2013 at 15:14 | Source: CNBC-TV18
Nomura has a buy whereas Antique has a sell on Ranbaxy.
Sep 16, 2013 at 09:00 | Source: CNBC-TV18
Import alert issued by USFDA on Ranbaxy's Mohali plant could not only be negative for the stock but according to the analyst community Ranbaxy could be on its last legs for having a good strong base in the US.
Aug 30, 2013 at 16:20 | Source: CNBC-TV18
Sources indicate that the deficiencies noted during DCGI inspections are not serious enough to attract suspension charges
Jul 02, 2013 at 17:29 | Source: Moneycontrol.com
Drug maker Ranbaxy Labs rose 6.5 percent to close at Rs 345.25 after USFDA told CNBC-TV18 that there is no proof of data reliability issues other than at 3 units that are Paonta Sahib, Batamandi & Dewas.
Jun 25, 2013 at 12:12 | Source: IBNLive.com
The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs.
Jun 24, 2013 at 15:16 | Source: Moneycontrol.com
The stock hit a near 4-year low after a news report said the US FDA may have issued a form 483 to its Mohali facility. The company has already pleaded guilty to felony charges related to manufacturing practises at its Dewas and Paonta Sahib plants.
Jun 05, 2013 at 09:54 | Source: IBNLive.com
The PIL is seeking prosecution of all Ranbaxy directors and sealing of its manufacturing units at Paonta Sahib and Devas.
May 22, 2013 at 20:09 | Source: CNBC-TV18
Diiachi says that certain former shareholders "misrepresented critical information".